Gilead Sciences (GILD) Long-Term Debt Issuances (2010 - 2024)
Gilead Sciences posted quarterly Long-Term Debt Issuances of $3.5 billion for Q4 2024, up 346300.0% year-on-year from N/an in Q1 2024, and up 346300.0% on a QoQ basis from $1.0 million in Q4 2023.
Gilead Sciences (GILD) has 10 years of Long-Term Debt Issuances data on file, last reported at $3.5 billion in Q4 2024.
- For the quarter ending Q4 2024, Long-Term Debt Issuances rose 346300.0% year-over-year to $3.5 billion; the trailing twelve-month figure through Dec 2024 stood at $3.5 billion (up 247.89% YoY), and the FY2024 full-year result was $3.5 billion, up 74.95% from the prior year.
- Long-Term Debt Issuances for Q4 2024 stood at $3.5 billion, up from $1.0 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $3.5 billion in Q4 2024 and bottomed at $1.0 million in Q4 2023.
- The 3-year median for Long-Term Debt Issuances is $995.0 million (2020), against an average of $1.5 billion.
- Peak annual rise in Long-Term Debt Issuances reached 346300.0% in 2024, while the deepest fall reached 346300.0% in 2024.
- A 3-year view of Long-Term Debt Issuances shows it stood at $995.0 million in 2020, then slumped by 99.9% to $1.0 million in 2023, then jumped by 346300.0% to $3.5 billion in 2024.
- The last three Long-Term Debt Issuances figures came in at $3.5 billion (Q4 2024), $1.0 million (Q4 2023), and $995.0 million (Q4 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 7.99 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 3.96 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.46 Bn |
| Dec 31, 2024 | 3.46 Bn |
| Dec 31, 2023 | 1.00 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Dec 31, 2020 | 995.00 Mn |
| Dec 31, 2020 | 995.00 Mn |
| Dec 31, 2017 | 5.99 Bn |
| Dec 31, 2017 | 5.99 Bn |
| Sep 30, 2017 | 2.99 Bn |
| Sep 30, 2017 | 2.99 Bn |
| Jun 30, 2016 | 861.00 Mn |
| Jun 30, 2016 | 861.00 Mn |
| Mar 31, 2016 | 95.00 Mn |
| Mar 31, 2016 | 95.00 Mn |
| Dec 31, 2015 | 184.00 Mn |
| Dec 31, 2015 | 184.00 Mn |
| Sep 30, 2015 | 600.00 Mn |
| Sep 30, 2015 | 600.00 Mn |
| Jun 30, 2015 | -154.00 Mn |
| Jun 30, 2015 | -154.00 Mn |
| Mar 31, 2015 | 154.00 Mn |
| Mar 31, 2015 | 154.00 Mn |
| Dec 31, 2014 | -1.42 Bn |
| Dec 31, 2014 | -1.42 Bn |
| Sep 30, 2014 | -1.00 Mn |
| Sep 30, 2014 | -1.00 Mn |
| Jun 30, 2014 | -2.00 Mn |
| Jun 30, 2014 | -2.00 Mn |
| Mar 31, 2014 | 3.97 Bn |
| Mar 31, 2014 | 3.97 Bn |
| Dec 31, 2012 | -733,000.00 |
| Dec 31, 2012 | -733,000.00 |
| Mar 31, 2012 | 2.14 Bn |
| Mar 31, 2012 | 2.14 Bn |
| Dec 31, 2011 | -951.22 Mn |
| Dec 31, 2011 | -951.22 Mn |
| Mar 31, 2011 | 987.37 Mn |
| Mar 31, 2011 | 987.37 Mn |
| Dec 31, 2010 | -2.46 Bn |
| Dec 31, 2010 | -2.46 Bn |